Director/PDMR Shareholding
June 30, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that Ordinary Shares ("Shares") and American Depositary Shares ("ADSs") in the
Company, as set out below, have been acquired today for the Non-Executive
Directors, being the part of their total fees that are paid in shares for the
period of service from April 1 to June 30, 2016.
Type of Security (1) Number of Shares/ADSs
Dominic Blakemore Shares 150
Olivier Bohuon Shares 134
William Burns Shares 190
Gail Fosler ADSs 13
Dr. Steven Gillis ADSs 61
Dr. David Ginsburg ADSs 57
Susan Kilsby ADSs 189
Sara Mathew ADSs 54
Anne Minto Shares 179
Albert Stroucken ADSs 17
(1) One ADS is equal to three Shares.
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ
respectively at £44.6306 per Share and $182.7877 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
of the Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people
with rare diseases and other highly specialized conditions. We strive to
develop best-in-class products, many of which are available in more than 100
countries, across core therapeutic areas including Hematology, Immunology,
Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine
/ Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an
emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com